"Ritonavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D019438
|
| MeSH Number(s) |
D02.886.675.653 D03.383.129.708.653
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ritonavir".
Below are MeSH descriptors whose meaning is more specific than "Ritonavir".
This graph shows the total number of publications written about "Ritonavir" by people in this website by year, and whether "Ritonavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ritonavir" by people in Profiles.
-
Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2023 02; 95(2):e28471.
-
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Infect. 2023 03; 86(3):248-255.
-
HIV protease inhibitor ritonavir induces renal fibrosis and dysfunction: role of platelet-derived TGF-ß1 and intervention via antioxidant pathways. AIDS. 2020 06 01; 34(7):989-1000.
-
HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-ß1 and can be suppressed by exogenous carbon monoxide. PLoS One. 2017; 12(10):e0187185.
-
Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Ann Pharmacother. 2014 Mar; 48(3):395-403.
-
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011 Sep 20; 155(6):402; author reply 403.
-
Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J. 2009 Dec; 28(12):1127-9.
-
Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir. HIV Clin Trials. 2009 Sep-Oct; 10(5):328-36.
-
Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy. 2002 Oct; 22(10):1312-6.
-
Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother. 2002 Apr; 36(4):702-6.